Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study.

To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP).

Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy.

Caveolin-1 was overexpressed in 644 (20. 6%) patients and was associated with higher pathological Gleason sum (P = 0. 002) and lymph node metastases (P = 0. 05). Within a median (interquartile range) follow-up of 38 (21-66) months, 617 (19. 8%) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0. 004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1. 21, P = 0. 037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0. 021).

We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.

BJU international. 2015 Jul 18 [Epub ahead of print]

Romain Mathieu, Tobias Klatte, Ilaria Lucca, Aurélie M Beutcha, Christian Seitz, Pierre I Karakiewicz, Harun Fajkovic, Maxine Sun, Yair Lotan, Douglas S Scherr, Francesco Montorsi, Alberto Briganti, Morgan Rouprêt, Vitaly Margulis, Michael Rink, Luis A Kluth, Malte Rieken, Lukas Kenner, Martin Susani, Brian D Robinson, Evanguelos Xylinas, Wolgang Loidl, Shahrokh F Shariat

Department of Urology, General Hospital, Vienna, Austria. , Department of Urology, General Hospital, Vienna, Austria. , Department of Urology, General Hospital, Vienna, Austria. , Department of Urology, General Hospital, Vienna, Austria. , Department of Urology, General Hospital, Vienna, Austria. , Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada. , Department of Urology, General Hospital, Vienna, Austria. , Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada. , Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. , Department of Urology, Weill Cornell Medical College, New York, NY, USA. , Department of Urology, Vita-Salute San Raffaele University, Milan, Italy. , Department of Urology, Vita-Salute San Raffaele University, Milan, Italy. , Academic Department of Urology, La Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, Paris, France. , Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. , Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. , Department of Urology, University Hospital Basel, Basel, Switzerland. , Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria. , Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria. , Department of Urology, Weill Cornell Medical College, New York, NY, USA. , Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France. , Department of Urology, Krankenhaus der Barmherzigen Schwestern, Linz, Austria. , Department of Urology, General Hospital, Vienna, Austria.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe